Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 3Head & Neck 2Genitourinary 1

Conditions

Breast Neoplasms 125Neoplasm Metastasis 17Ovarian Neoplasms 12Endometrial Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Hereditary Sensory and Autonomic Neuropathies 5Colorectal Neoplasms 5Advanced Breast Cancer 5Squamous Cell Carcinoma of Head and Neck 4Stomach Neoplasms 3Recurrence 3Neoplasms by Site 3Head and Neck Neoplasms 3Carcinoma, Lobular 3Breast Diseases 3Breast Cancer Metastatic 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Multiple Endocrine Neoplasia Type 1 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumors 2Urologic Neoplasms 1Urogenital Neoplasms 1

Interventions

Cisplatin 6pembrolizumab 5Nivolumab 5palbociclib 4durvalumab 4Pemetrexed 4atezolizumab 3abemaciclib 3Fulvestrant 3Carboplatin 3Anastrozole 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2relatlimab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Radiosurgery 2Paclitaxel 2Letrozole 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Bevacizumab 2AZD9833 2trametinib 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms by Site × Fulvestrant × 1 year × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio, Inc

Phase 1 Active not recruiting
134 enrolled
BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡